Skip to main content

Advertisement

SpringerLink
Log in

Risk Factors, Epidemiology and Treatment Strategies for Metabolic Bone Disease in Patients with Neurological Disease

  • Secondary Causes of Osteoporosis (S Warden, Section Editor)
  • Published:
Current Osteoporosis Reports Aims and scope Submit manuscript

Abstract

Metabolic bone disease is a major public health concern, especially when it manifests as hip fracture which carries significant morbidity and mortality. Individuals with neurological disease are at higher risk of osteopenia, osteoporosis and fragility fracture compared to age-matched controls, yet this is under-appreciated by these patients. Clinician attention to this topic is therefore of importance and should address the bone health of men as well as women, a group in whom it may be an under-recognised problem. Evidence for optimal management of bone health in neurological disease remains to be defined, but a growing literature provides some useful guidance. This review focuses on two conditions, multiple sclerosis and Parkinson’s disease, where research has been active over recent years. In neuroinflammation, shared immunological pathways between bone and brain are a current domain of interest and it will be intriguing to interrogate the action of emerging immunotherapies on these dual compartments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Klop C, Welsing PM, Cooper C, et al. Mortality in British hip fracture patients, 2000–2010: a population-based retrospective cohort study. Bone. 2014;66:171–7.

    Article  PubMed  Google Scholar 

  2. Keene GS, Parker MJ, Pryor GA. Mortality and morbidity after hip fractures. BMJ. 1993;307(6914):1248–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Watts NB. GLOW investigators. Insights from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Nat Rev Endocrinol. 2014;10(7):412–22. This study highlights medical co-morbidities that are associated with an increased risk of osteoporosis and fracture in the largest longitudinal study of bone health to date.

  4. National Institute for Health and Care Excellence. Osteoporosis: assessing the risk of fragility fracture (CG146). 2012 Aug [accessed 2016 Jan 3]. Available from URL: https://www.nice.org.uk/guidance/conditions-and-diseases/diabetes-and-other-endocrinal--nutritional-and-metabolic-conditions/osteoporosis.

  5. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Gregson CL, Dennison EM, Compston JE, et al. Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study. Osteoporos Int. 2014;25(1):85–95.

    Article  CAS  PubMed  Google Scholar 

  7. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502–17.

    Article  CAS  PubMed  Google Scholar 

  8. Moen SM, Celius EG, Sandvik L, Nordsletten L, Eriksen EF, Holmøy T. Low bone mass in newly diagnosed multiple sclerosis and clinically isolated syndrome. Neurology. 2011;77(2):151–7.

    Article  CAS  PubMed  Google Scholar 

  9. Batista S, Teter B, Sequeira K, et al. Cognitive impairment is associated with reduced bone mass in multiple sclerosis. Mult Scler. 2012;18(10):1459–65.

    Article  PubMed  Google Scholar 

  10. Straub RH, Cutolo M, Pacifici R. Semin Arthritis Rheum. 2015;45(2):220–8.

    Article  PubMed  Google Scholar 

  11. Josyula S, Mehta BK, Karmon Y, et al. The nervous system’s potential role in multiple sclerosis associated bone loss. J Neurol Sci. 2012;319(1–2):8–14.

    Article  PubMed  Google Scholar 

  12. Zhao W, Liu Y, Cahill CM, Yang W, Rogers JT, Huang X. The role of T-cells in osteoporosis: an update. Int J Clin Exp Pathol. 2009;2(6):544–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Ding C, Parameswaran V, Udayan R, Burgess J, Jones G. Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study. J Clin Endocrinol Metab. 2008;93(5):1952–8.

    Article  CAS  PubMed  Google Scholar 

  14. Eriksson AL, Movérare-Skrtic S, Ljunggren Ö, Karlsson M, Mëllstrom D, Ohlsson C. High‐Sensitivity CRP is an independent risk factor for all fractures and vertebral fractures in elderly men: the MrOS Sweden study. J Bone Miner Res. 2014;29(2):418–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Takayanagi H, Kim S, Matsuo K, et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β. Nature. 2002;416(6882):744–9.

    Article  CAS  PubMed  Google Scholar 

  16. Vogt HJ, ten Kate J, Drent RJ, Polman CH, Hupperts R. Increased osteopontin plasma levels in multiple sclerosis patients correlate with bone-specific markers. Mult Scler. 2010;16(4):443–9.

    Article  CAS  PubMed  Google Scholar 

  17. Hamrick MW. Leptin, bone mass and the thrifty phenotype. J Bone Miner Res. 2004;19(10):1607–11.

    Article  CAS  PubMed  Google Scholar 

  18. Dobson R, Yarnall A, Noyce AJ, Giovannoni G. Bone health in chronic neurological diseases: a focus on multiple sclerosis and parkinsonian syndromes. Pract Neurol. 2013;13(2):70–9.

    Article  PubMed  Google Scholar 

  19. Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol. 2008;7:268–77.

    Article  PubMed  Google Scholar 

  20. Ramagopalan SV, Dyment DA, Cader MZ, et al. Rare variants in the CYP27B1 gene are associated with multiple sclerosis. Ann Neurol. 2011;70(6):881–6.

    Article  CAS  PubMed  Google Scholar 

  21. Ban M, Callier S, Mero IL, et al. No evidence of association between mutant alleles of the CYP27B1 gene and multiple sclerosis. Ann Neurol. 2013;73(3):430–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Nieves J, Cosman F, Herbert J, Shen V, Lindsay R. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology. 1994;44(9):1687–92.

    Article  CAS  PubMed  Google Scholar 

  23. Cosman F, Nieves J, Komar BS, et al. Fracture history and bone loss in patients with MS. Neurology. 1998;51(4):1161–5.

    Article  CAS  PubMed  Google Scholar 

  24. Terzi T, Terzi M, Tander B, Cantϋrk F, Onar M. Changes in bone mineral density and bone metabolism markers in premenopausal women with multiple sclerosis and the relationship to clinical variables. J Clin Neurosci. 2010;17(10):1260–4.

    Article  PubMed  Google Scholar 

  25. Ozgocmen S, Bulut S, Ilhan N, Gulkesen A, Ardigoclu O, Özkan Y. Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity. J Bone Miner Metab. 2005;23(4):309–13.

    Article  PubMed  Google Scholar 

  26. Steffensen LH, Mellgren SI, Kampman MT. Predictors and prevalence of low bone mineral density in fully ambulatory persons with multiple sclerosis. J Neurol. 2010;257(3):410–8.

    Article  PubMed  Google Scholar 

  27. Steffensen LH, Jørgensen L, Straume B, Mellgren SI, Kampman MT. Can Vitamin D3 supplementation prevent bone loss in persons with MS? A placebo-controlled trial. J Neurol. 2011;258(9):1624–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Moen SM, Celius EG, Sandvik L, et al. Bone turnover and metabolism in patients with early multiple sclerosis and prevalent bone mass deficit: a population-based case-control study. PLoS One. 2012;7(9):e45703. Highlights the need to consider metabolic bone disease in early multiple sclerosis, before significant fixed disability has developed.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Triantafyllou N, Lambrinoudaki I, Thoda P, et al. Lack of association between vitamin D levels and bone mineral density in patients with multiple sclerosis. J Neurol Sci. 2012;313(1–2):137–41.

    Article  CAS  PubMed  Google Scholar 

  30. Nilsagård Y, Gunn H, Freeman J, et al. Falls in people with MS—an individual data meta-analysis from studies from Australia, Sweden, United Kingdom and the United States. Mult Scler. 2015;21(1):92–100.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Troiano RA, Jotkowitz A, Cook SD, Bansil S, Zito G. Rate and types of fractures in corticosteroid-treated multiple sclerosis patients. Neurology. 1992;42(7):1389–91.

    Article  CAS  PubMed  Google Scholar 

  32. Moen SM, Celius EG, Nordsletten L, Holmøy T. Fractures and falls in patients with newly diagnosed clinically isolated syndrome and multiple sclerosis. Acta Neurol Scand Suppl. 2011;191:79–82.

    Article  PubMed  Google Scholar 

  33. Mazumder R, Murchison S, Bourdette D, Cameron M. Falls in people with multiple sclerosis compared with falls in healthy controls. PLoS One. 2014;9(9), e107620.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Nilsagård Y, Lundholm C, Denison E, Gunnarsson LG. Predicting accidental falls in people with multiple sclerosis—a longitudinal study. Clin Rehabil. 2009;23(3):259–69.

    Article  PubMed  Google Scholar 

  35. Marrie RA, Cutter G, Tyry T, Vollmer T. A cross-sectional study of bone health in multiple sclerosis. Neurology. 2009;73(17):1394–8.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Haselkorn JK, Hughes C, Rae-Grant A, et al. Summary of comprehensive systematic review: rehabilitation in multiple sclerosis. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2015;85(21):1896–903.

    Article  PubMed  Google Scholar 

  37. Tüzun S, Altintas A, Karacan I, Tangürek S, Saip S, Siva A. Bone status in multiple sclerosis: beyond corticosteroids. Mult Scler. 2003;9(6):600–4.

    Article  PubMed  Google Scholar 

  38. Tyblova M, Kalincik T, Zikan V, Havrdova E. Impaired ambulation and steroid therapy impact negatively on bone health in multiple sclerosis. Eur J Neurol. 2015;22(4):624–32.

    Article  CAS  PubMed  Google Scholar 

  39. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale. Neurology. 1983;33(11):1444–52.

    Article  CAS  PubMed  Google Scholar 

  40. Weinstock-Guttman B, Gallagher E, Baier M, et al. Risk of bone loss in men with multiple sclerosis. Mult Scler. 2004;10(2):170–5.

    Article  PubMed  Google Scholar 

  41. Zikán V, Týblova M, Raška Jr I, et al. Bone mineral density and body composition in men with multiple sclerosis chronically treated with low-dose glucocorticoids. Physiol Res. 2012;61(4):405–17.

    PubMed  Google Scholar 

  42. Zorzon M, Zivadinov R, Locatelli L, et al. Long-term effects of intravenous high dose methylprednisolone pulses in bone mineral density in patients with multiple sclerosis. Eur J Neurol. 2005;12(7):550–6.

    Article  CAS  PubMed  Google Scholar 

  43. Gibson JC, Summers GD. Bone health in multiple sclerosis. Osteoporos Int. 2011;22(12):2935–49.

    Article  CAS  PubMed  Google Scholar 

  44. Sioka C, Papkonstantinou S, Fotopoulos A, et al. Bone mineral density in ambulatory patients with multiple sclerosis. Neurol Sci. 2011;32(5):819–24.

    Article  PubMed  Google Scholar 

  45. Gough AK, Lilley J, Eyre S, Holder RL, Emery P. Generalised bone loss in patients with early rheumatoid arthritis. Lancet. 1994;344(8914):23–7.

    Article  CAS  PubMed  Google Scholar 

  46. Then Bergh F, Kϋmpfel T, Schumann E, et al. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis—reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. BMC Neurol. 2006;6:19.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  47. Ravnborg M, Sørensen PS, Andersson M, et al. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurol. 2010;9(7):672–80.

    Article  CAS  PubMed  Google Scholar 

  48. Olsson A, Oturai DB, Sørensen PS, Oturai PS, Oturai AB. Short-term, high-dose glucocorticoid treatment does not contribute to reduced bone mineral density in patients with multiple sclerosis. Mult Scler. 2015;21(12):1557–65. Indicates that short pulsed corticosteroids used for MS relapse are likely to be safe from a BMD point of view.

    Article  CAS  PubMed  Google Scholar 

  49. Formica CA, Cosman F, Nieves J, Herbert J, Lindsay R. Reduced bone mass and fat-free mass in women with multiple sclerosis: effects of ambulatory status and glucocorticoid use. Calcif Tissue Int. 1997;61(2):129–33.

    Article  CAS  PubMed  Google Scholar 

  50. Bazelier M, van Staa T, Uitdehaag MJ, et al. The risk of fracture in patients with multiple sclerosis: the UK general practice research database. J Bone Miner Res. 2011;26(9):2271–9.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Ce P, Gedizlioglu M, Gelal F, Coban P, Ozbek G. Avascular necrosis of the bones: an overlooked complication of pulse steroid treatment of multiple sclerosis. Eur J Neurol. 2006;13(8):857–61.

    Article  PubMed  Google Scholar 

  52. Sahraian MA, Yadegari S, Azarpajouh R, Forughipour M. Avascular necrosis of the femoral head in multiple sclerosis: report of five patients. Neurol Sci. 2012;33(6):1443–6.

    Article  CAS  PubMed  Google Scholar 

  53. Cocksedge S, Freestone S, Martin JF. Unrecognised femoral fractures in patients with paraplegia due to multiple sclerosis. Br Med J (Clin Res Ed). 1984;289(6440):309.

    Article  CAS  Google Scholar 

  54. Bazelier MT, Bentzen J, Vestergaard P, et al. The risk of fracture in incident multiple sclerosis patients: the Danish national health registers. Mult Scler. 2012;18(11):1609–16.

    Article  PubMed  Google Scholar 

  55. Bazelier MT, van Staa TP, Uitdehaag BM, et al. Risk of fractures in patients with multiple sclerosis. A population-based cohort study. Neurology. 2012;78(24):1967–73. A large population-based study examining the risk of fracture in patients with MS, leading to the development of a novel method of estimating fracture risk in this population.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Dobson R, Ramagopalan S, Giovannoni G. Risk of fractures in patients with multiple sclerosis: a population-based cohort study. Neurology. 2012;79(18):1934–5. Comment on: Risk of fractures in patients with multiple sclerosis: a population-based cohort study. [Neurology 2012].

    Article  PubMed  Google Scholar 

  57. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359(9319):1761–7.

    Article  PubMed  Google Scholar 

  58. Ayatollahi A, Mohajeri-Tehrani MR, Nafissi S. Factors affecting bone mineral density in multiple sclerosis patients. Iran J Neurol. 2013;12(1):19–22.

    PubMed  PubMed Central  Google Scholar 

  59. Dennison EM, Compston JE, Flahive J, et al. Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone. 2012;50(6):1288–93.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Ramagopalan SV, Seminog O, Goldacre R, Goldacre MJ. Risk of fractures in patients with multiple sclerosis: record-linkage study. BMC Neurol. 2012;12:135.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Bhattacharya RK, Vaishnav N, Dubinsky RM. Is there an increased risk of hip fracture in multiple sclerosis? Analysis of the nationwide inpatient sample. J Multidiscip Healthc. 2014;7:119–22.

    Article  PubMed  PubMed Central  Google Scholar 

  62. FRAX® WHO Fracture Risk Assessment Tool [on-line] [accessed 2016 Jan 7]. Available from URL: https://www.shef.ac.uk/FRAX/index.aspx

  63. Hippisley-Cox J, Coupland C. Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ. 2012;344, e3427.

    Article  PubMed  Google Scholar 

  64. Bazelier MT, van Staa TP, Uitedehaag BM, et al. A simple score for estimating the long-term risk of fracture in patients with multiple sclerosis. Neurology. 2012;79(9):922–8.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Dobson R, Leddy SG, Gangadharan S, Giovannoni G. Assessing fracture risk in people with MS: a service development study comparing three fracture risk scoring systems. BMJ Open. 2013; 3 (3). Highlights the deficit in fracture risk calculators for the MS population.

  66. Dobson R, Ramagopalan S, Giovannoni G. Bone health and multiple sclerosis. Mult Scler. 2012;18(11):1522–8.

    Article  PubMed  Google Scholar 

  67. Shuhaibar M, McKenna MJ, Au-Yeong M, Redmond JM. Favourable effect of immunomodulatory therapy on bone mineral density in multiple sclerosis. Ir J Med Sci. 2009;178(1):43–5.

    Article  CAS  PubMed  Google Scholar 

  68. Weinstock-Guttman B, Hong J, Santos R, et al. Interferon-β modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients. Mult Scler. 2006;12(5):541–50.

    Article  CAS  PubMed  Google Scholar 

  69. Abraham AK, Ramanathan M, Weinstock-Guttman B, Mager DE. Mechanisms of interferon-β effects on bone homeostasis. Biochem Pharmacol. 2009;77(12):1757–62.

    Article  CAS  PubMed  Google Scholar 

  70. Gillespie LD, Robertson MC, Gillespie WJ, et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2012;9, CD007146.

    PubMed  Google Scholar 

  71. Holmøy T, Torkildsen Ø, Myhr K-M, Løken-Amsrud KI. Vitamin D supplementation and monitoring in multiple sclerosis: who, when and wherefore. Acta Neurol Scand Suppl. 2012;195:63–9.

    Article  PubMed  Google Scholar 

  72. Chapuy MC, Arlot MF, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med. 1992;327(23):1637–42.

    Article  CAS  PubMed  Google Scholar 

  73. Tai V, Leung W, Grey A, Reid IR, Bolland MJ. Calcium intake and bone mineral density: systematic review and meta-analysis. BMJ. 2015;351:h4183.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  74. Bolland MJ, Leung W, Tai V, et al. Calcium intake and risk of fracture: systematic review. BMJ. 2015;351:h4580.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  75. Grey A, Bolland M. Web of industry, advocacy and academia in the management of osteoporosis. BMJ. 2015;351:h3170.

    Article  PubMed  Google Scholar 

  76. Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386(9996):896–912.

    Article  CAS  PubMed  Google Scholar 

  77. de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam study. Neurology. 2004;63(7):1240–4.

    Article  PubMed  Google Scholar 

  78. Schrag A, Ben-Schlomo Y, Quinn N. How common are complications of Parkinson’s disease? J Neurol. 2002;249(4):419–23.

    Article  PubMed  Google Scholar 

  79. Martignoni E, Godi L, Citterio A, et al. Comorbid disorders and hospitalisation in Parkinson’s disease: a prospective study. Neurol Sci. 2004;25(2):66–71.

    Article  CAS  PubMed  Google Scholar 

  80. Wielinski CL, Erickson-Davis C, Wichmann R, Walde-Douglas M, Parashos SA. Falls and injuries resulting from falls among patients with Parkinson’s disease and other Parkinsonian syndromes. Mov Disord. 2005;20(4):410–5.

    Article  PubMed  Google Scholar 

  81. Temlett JA, Thompson PD. Reasons for admission to hospital for Parkinson’s disease. Intern Med J. 2006;36(8):524–6.

    Article  CAS  PubMed  Google Scholar 

  82. Johnell O, Sernbo I. Health and social status in patients with hip fractures and controls. Age Ageing. 1986;15(5):285–91.

    Article  CAS  PubMed  Google Scholar 

  83. Sato Y, Manabe S, Kuno H, Oizumi K. Amelioration of osteopenia and hypovitaminosis D by 1α-hydroxyvitamin D3 in elderly patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1999;66(1):64–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Sato Y, Iwamoto J, Kanoko T, Satoh K. Alendronate and Vitamin D2 for prevention of hip fracture in Parkinson’s disease: a randomized controlled trial. Mov Disord. 2006;21(7):924–9.

    Article  PubMed  Google Scholar 

  85. Sato Y, Honda Y, Iwamoto J. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology. 2007;68(12):911–5.

    Article  CAS  PubMed  Google Scholar 

  86. Sato Y, Kikuyama M, Oizumi K. High prevalence of Vitamin D deficiency and reduced bone mass in Parkinson’s disease. Neurology. 1997;49(5):1273–8.

    Article  CAS  PubMed  Google Scholar 

  87. Invernizzi M, Carda S, Viscontini GS, Cisari C. Osteoporosis in Parkinson’s disease. Parkinsonism Relat Disord. 2009;15(5):339–46.

    Article  PubMed  Google Scholar 

  88. Fasano A, Visanji NP, Liu LW, Lang AE, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol. 2015;14(6):625–39.

    Article  CAS  PubMed  Google Scholar 

  89. Jaafar AF, Gray WK, Porter B, Turnbull EJ, Walker RW. A cross-sectional study of the nutritional status of community-dwelling people with idiopathic Parkinson’s disease. BMC Neurol. 2010;10:124.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Sato Y, Kaji M, Tsuru T, Oizumi K. Risk factors for hip fracture among elderly patients with Parkinson’s disease. J Neurol Sci. 2001;182(2):89–93.

    Article  CAS  PubMed  Google Scholar 

  91. Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson’s disease: diagnosis, biomarkers, and treatment. Lancet Neurol. 2012;11(8):697–707.

    Article  PubMed  Google Scholar 

  92. Abou-Raya S, Helmii M, Abou-Raya A. Bone and mineral metabolism in older adults with Parkinson’s disease. Age Ageing. 2009;38(6):675–80.

    Article  PubMed  Google Scholar 

  93. Pressley JC, Louis ED, Tang MX, et al. The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism. Neurology. 2003;60(1):87–93.

    Article  CAS  PubMed  Google Scholar 

  94. Melton 3rd LJ, Leibson CL, Achenbach SJ, et al. Fracture risk after the diagnosis of Parkinson’s disease: influence of concomitant dementia. Mov Disord. 2006;21(9):1361–7.

    Article  PubMed  Google Scholar 

  95. Shirazi HA, Rasouli J, Ciric B, Rostami A, Zhang GX. 1,25-Dihydroxyvitamin D3 enhances neural stem cell proliferation and oligodendrocyte differentiation. Exp Mol Pathol. 2015;98(2):240–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Fink HA, Kuskowski MA, Orwoll ES, Cauley JA, Ensrud KE, Osteoporotic Fractures in Men Study Group. Association between Parkinson’s disease and low bone density and falls in older men: the osteoporotic fractures in men study. J Am Geriatr Soc. 2005;53(9):1559–64.

    Article  PubMed  Google Scholar 

  97. Schneider JL, Fink HA, Ewing SK, Ensrud KE, Cummings SR, Study of Osteoporotic Fractures (SOF) Research Group. The association of Parkinson’s disease with bone mineral density and fracture in older women. Osteoporos Int. 2008;19(7):1093–7.

    Article  CAS  PubMed  Google Scholar 

  98. Llewellyn DJ, Lang IA, Langa KM, et al. Vitamin D and risk of cognitive decline in elderly persons. Arch Intern Med. 2010;170(13):1135–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Toffanello ED, Coin A, Perissinotto E, et al. Vitamin D deficiency predicts cognitive decline in older men and women. Neurology. 2014;83(24):2292–8.

    Article  CAS  PubMed  Google Scholar 

  100. Evatt ML, DeLong MR, Khazai N, et al. Prevalence of Vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol. 2008;65(10):1348–52.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Grisso JA, Kelsey JL, Strom BL, et al. Risk factors for falls as a cause of hip fracture in women. N Engl J Med. 1991;324(19):1326–31.

    Article  CAS  PubMed  Google Scholar 

  102. Woodford H, Walker R. Emergency hospital admissions in idiopathic Parkinson’s disease. Mov Disord. 2005;20(9):1104–8.

    Article  PubMed  Google Scholar 

  103. Williams DR, Watt HC, Lees AJ. Predictors of falls and fractures in bradykinetic rigid syndromes: a retrospective study. J Neurol Neurosurg Psychiatry. 2006;77(4):468–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427–42.

    Article  CAS  PubMed  Google Scholar 

  105. Ali K, Morris HR. Parkinson’s disease: chameleons and mimics. Pract Neurol. 2015;15(1):14–25.

    Article  PubMed  Google Scholar 

  106. Koller WC, Glatt S, Vetere-Overfield B, Hassanein R. Falls and Parkinson’s disease. Clin Neuropharmacol. 1989;12(2):98–105.

    Article  CAS  PubMed  Google Scholar 

  107. Ashburn A, Stack E, Pickering RM, Ward CD. A community-dwelling sample of people with Parkinson’s disease: characteristics of fallers and non-fallers. Age Ageing. 2001;30(1):47–52.

    Article  CAS  PubMed  Google Scholar 

  108. Balash Y, Peretz C, Leibovich G, Herman T, Hausdorff JM, Giladi N. Falls in outpatients with Parkinson’s disease. Frequency, impact and identifying factors. J Neurol. 2005;252(11):1310–5.

    Article  CAS  PubMed  Google Scholar 

  109. Eng ML, Lyons KE, Pahwa R. Prevalence of bone mineral density screening in Parkinson’s disease clinic outpatients. Mov Disord. 2006;21(12):2265–6.

    Article  PubMed  Google Scholar 

  110. Bloem BR, Grimbergen YA, Cramer M, Willemsen M, Zwinderman AH. Prospective assessment of falls in Parkinson’s disease. J Neurol. 2001;248(11):950–8.

    Article  CAS  PubMed  Google Scholar 

  111. Wood BH, Bilclough JA, Bowron A, Walker RW. Incidence and prediction of falls in Parkinson’s disease: a prospective multidisciplinary study. J Neurol Neurosurg Psychiatry. 2002;72(6):721–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Cheng KY, Lin WC, Chang WN, et al. Factors associated with fall-related fractures in Parkinson’s disease. Parkinsonism Relat Disord. 2014;20(1):88–92. Provides background into fracture risk in PD.

    Article  PubMed  Google Scholar 

  113. Arbouw ME, Movig KL, van Staa TP, Egberts AC, Souverein PC, de Vries F. Dopaminergic drugs and the risk of hip or femur fracture: a population based study. Osteoporos Int. 2011;22(7):2197–204.

    Article  CAS  PubMed  Google Scholar 

  114. Wood B, Walker R. Osteoporosis in Parkinson’s disease. Mov Disord. 2005;20(12):1636–40.

    Article  PubMed  Google Scholar 

  115. Lee SH, Kim MJ, Kim BJ, et al. Hyperhomocysteinemia due to levodopa treatment as a risk factor for osteoporosis in patients with Parkinson’s disease. Calcif Tissue Int. 2010;86(2):132–41.

    Article  PubMed  CAS  Google Scholar 

  116. Brandt-Christiansen M, Lopez AG, Nilsson FM, Andersen PK, Kessing LV. Parkinson’s disease and antidepressant drug treatment—a case register study. Parkinsonism Relat Disord. 2007;13(7):406–10.

    Article  Google Scholar 

  117. van den Brand MW, Samson MM, Pouwels S, et al. Use of anti-depressants and risk of fracture of the hip or femur. Osteoporos Int. 2009;20(10):1705–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Bhattacharya RK, Dubinsky RM, Lai SM, Dubinsky H. Is there an increased risk of hip fracture in Parkinson’s disease? A nationwide inpatient sample. Mov Disord. 2012;27(11):1440–3.

    Article  PubMed  Google Scholar 

  119. Torsney KM, Noyce AJ, Doherty KM, Bestwick JP, Dobson R, Lees AJ. Bone health in Parkinson’s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2014;85(10):1159–66.

    Article  PubMed  PubMed Central  Google Scholar 

  120. Fink HA, Kuskowski MA, Taylor BC, et al. Association of Parkinson’s disease with accelerated bone loss, fractures and mortality in older men: the Osteoporotic Fractures in Men (MrOS) study. Osteoporos Int. 2008;19(9):1277–82.

    Article  CAS  PubMed  Google Scholar 

  121. Kao CH, Chen CC, Wang SJ, Chia LG, Yeh SH. Bone mineral density in patients with Parkinson’s disease measured by dual photon absorptiometry. Nucl Med Commun. 1994;15(3):173–7.

    Article  CAS  PubMed  Google Scholar 

  122. Taggart H, Crawford V. Reduced bone mineral density of the hip in elderly patients with Parkinson’s disease. Age Ageing. 1995;24(4):326–8.

    Article  CAS  PubMed  Google Scholar 

  123. Lorefält B, Toss G, Granaries AK. Bone mass in elderly patients with Parkinson’s disease. Acta Neurol Scand. 2007;116(4):248–54.

    Article  PubMed  Google Scholar 

  124. Bezza A, Ouzzif Z, Naji H, et al. Prevalence and risk factors of osteoporosis in patients with Parkinson’s disease. Rheumatol Int. 2008;28(12):1205–9.

    Article  CAS  PubMed  Google Scholar 

  125. van den Bos F, Speelman AD, van Nimwegen M, et al. Bone mineral density and vitamin D status in Parkinson’s disease patients. J Neurol. 2013;260(3):754–60.

    Article  CAS  PubMed  Google Scholar 

  126. Zhao Y, Shen L, Ji HF. Osteoporosis risk and bone mineral density levels in patients with Parkinson’s disease: a meta-analysis. Bone. 2013;52(1):498–505.

    Article  PubMed  Google Scholar 

  127. Johnell O, Melton 3rd LJ, Atkinson EJ, O’Fallon M, Kurland LT. Fracture risk in patients with Parkinsonism: a population-based study in Olmsted County, Minnesota. Age Ageing. 1992;21(1):32–8.

    Article  CAS  PubMed  Google Scholar 

  128. Genever RW, Downes TW, Medcalf P. Fracture rates in Parkinson’s disease compared with age- and gender-matched controls: a retrospective cohort study. Age Ageing. 2005;34(1):21–4.

    Article  PubMed  Google Scholar 

  129. Pouwels S, Bazelier MT, de Boer A, et al. Risk of fracture in patients with Parkinson’s disease. Osteoporos Int. 2013;24(8):2283–90.

    Article  CAS  PubMed  Google Scholar 

  130. Coughlin L, Templeton J. Hip fractures in patients with Parkinson’s disease. Clin Orthop Relat Res. 1980;148:192–5.

    PubMed  Google Scholar 

  131. Eventov I, Moreno M, Geller E, Tardiman R, Salama R. Hip fractures in patients with Parkinson’s syndrome. J Trauma. 1983;23(2):98–101.

    Article  CAS  PubMed  Google Scholar 

  132. Turcotte R, Godin C, Duchesne R, Jodoin A. Hip fractures and Parkinson’s disease. A clinical review of 94 fractures treated surgically. Clin Orthop Relat Res. 1990; (256):132–6.

  133. Clubb VJ, Clubb SE, Buckley S. Parkinson’s disease patients who fracture their neck of femur: a review of outcome data. Injury. 2006;37(10):929–34.

    Article  CAS  PubMed  Google Scholar 

  134. Walker RW, Chaplin A, Hancock RL, Rutherford R, Gray WK. Hip fractures in people with idiopathic Parkinson’s disease: incidence and outcomes. Mov Disord. 2013;28(3):334–40.

    Article  PubMed  Google Scholar 

  135. Shribman S, Torsney K, Noyce AJ, Giovannoni G, Fearnley J, Dobson R. A service development study of the assessment and management of fracture risk in Parkinson’s disease. J Neurol. 2014;261(6):1153–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  136. Lyell V, Henderson E, Devine M, Gregson C. Assessment and management of fracture risk in patients with Parkinson’s disease. Age Ageing. 2015;44(1):34–41.

    Article  PubMed  Google Scholar 

  137. Goodwin VA, Richards SH, Taylor RS, Taylor AH, Campbell JL. The effectiveness of exercise interventions for people with Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2008;23(5):631–40.

    Article  PubMed  Google Scholar 

  138. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–22.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, UK

    S. Binks

  2. Blizard Institute, Queen Mary University, 4 Newark St, London, E1 2AT, UK

    R. Dobson

  3. St Georges Hospital, Blackshaw Rd, London, SW17 0QT, UK

    R. Dobson

Authors
  1. S. Binks
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Dobson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Dobson.

Ethics declarations

Conflict of Interest

Ruth Dobson has no conflicts of interest to declare.

Sophie Binks is in receipt of an NIHR fellowship (National Institute for Health Research, UK). The funder had no influence over this review article.

Human and Animal Rights and Informed Consent

This review article does not contain any original information on studies with human or animal subjects. Reference 65 (Dobson R, Leddy SG, Gangadharan S, Giovannoni G. Assessing fracture risk in people with MS: a service development study comparing three fracture risk scoring systems. BMJ Open. 2013 Mar 11; 3 (3)) was written by Dr Dobson and involved human subjects. Internal hospital ethical approval was gained for this work, details of which are given in the original article.

Additional information

This article is part of the Topical Collection on Secondary Causes of Osteoporosis

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Table 1

(DOCX 19 kb)

Supplementary Table 2

(DOCX 21 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Binks, S., Dobson, R. Risk Factors, Epidemiology and Treatment Strategies for Metabolic Bone Disease in Patients with Neurological Disease. Curr Osteoporos Rep 14, 199–210 (2016). https://doi.org/10.1007/s11914-016-0320-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11914-016-0320-5

Keywords

Search

Navigation